Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Pharmaron Beijing Co., Ltd.
康龍化成(北京)新藥技術股份有限公司
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 3759)

(I) POLL RESULTS OF THE FIRST EXTRAORDINARY GENERAL MEETING OF 2025; (II) APPOINTMENTS OF INDEPENDENT NON-EXECUTIVE DIRECTORS; AND (III) AMENDMENTS TO THE ARTICLES OF ASSOCIATION

The board (the "**Board**") of directors (the "**Directors**") of Pharmaron Beijing Co., Ltd. (康龍化成(北京)新藥技術股份有限公司) (the "**Company**") is pleased to announce that the First Extraordinary General Meeting of 2025 (the "**EGM**") of the Company was held by the Company at 6 Tai-He Road, Economic Technological Development Area, Beijing, the People's Republic of China (the "**PRC**") on Thursday, December 18, 2025 at 2:30 p.m. and all the resolutions set out below were voted by way of poll.

Reference is made to the notice of the EGM (the "**Notice**") and the circular (the "**Circular**") of the Company, both dated November 27, 2025. Unless otherwise defined, terms used herein shall have the same meanings as those defined in the Circular.

(I) POLL RESULTS OF THE FIRST EXTRAORDINARY GENERAL MEETING OF 2025 HELD ON DECEMBER 18, 2025

As at the date of the EGM, the total number of issued shares of the Company (the "**Shares**") is 1,770,932,225 Shares (comprising 1,476,658,400 A Shares and 294,273,825 H Shares (excluding any treasury H Shares)). On the day of the EGM, the Company held 7,263,300 treasury H Shares. Hence, the holders of these treasury H Shares must abstain from voting at the EGM. Consequently, the actual number of Shares which gave rise to voting rights at the EGM was 1,770,932,225 Shares.

The total number of Shares with voting rights represented by the Shareholders attending the EGM in person or by proxy was 860,821,389 Shares, representing approximately 48.6084% of the total number of Shares carrying voting rights of the Company. Saved as disclosed above, and to the best knowledge, information and belief of the Company, no Shareholder of the Company was required under Rule 13.40 of the Listing Rules to abstain from voting in favour of any of the resolutions at the EGM. No Shareholder was required under the Listing Rules to abstain from voting. No Shareholders have stated their intention in the Circular to vote against or to abstain from voting on any of the resolutions at the EGM.

At the time of the EGM, all Directors (including executive Directors Dr. LOU Boliang, Mr. LOU Xiaoqiang and Ms. ZHENG Bei, non-executive Directors Mr. LI Jiaqing and Ms. Wan Xuan, and independent non-executive Directors Ms. LI Lihua, Mr. Tsang Kwan Hung Benson and Mr. YU Jian) attended the EGM either in person or through electronic means.

The EGM were legally and validly convened in compliance with the requirements of the Company Law of the PRC and the Articles of Association. The chairman of the EGM was Dr. LOU Boliang, an executive Director.

In compliance with the requirements of the Listing Rules, the Company appointed Tricor Investor Services Limited (the Company's H Share registrar), the Company's supervisors, the Company's Shareholder representatives and Zhong Lun Law Firm (the Company's PRC legal adviser) as the scrutineers for the vote-taking at the EGM.

The poll results in respect of the respective resolutions at the EGM were as follows:

ORDINARY RESOLUTIONS		FOR		AGAINST		ABSTAIN	
		NUMBER OF VOTES (SHARES)	PERCENTAGE	NUMBER OF VOTES (SHARES)	PERCENTAGE	NUMBER OF VOTES (SHARES)	PERCENTAGE
1.	By-election of independent non-executive Director of the third session of the Board.	860,312,319	99.9409%	359,845	0.0418%	149,225	0.0173%
2.	Amendments to the Related Party/Connected Transactions Management Policy.	860,371,619	99.9478%	299,045	0.0347%	150,725	0.0175%
3.	Amendments to the External Guarantee Management Policy.	860,349,419	99.9452%	310,445	0.0361%	161,525	0.0188%
4.	Amendments to the Independent Non-executive Directors Working Policy.	860,373,420	99.9480%	288,744	0.0335%	159,225	0.0185%
5.	Amendments to the External Investment Management Policy.	860,355,644	99.9459%	293,145	0.0341%	172,600	0.0201%
6.	Amendments to the Special Storage and Use of Proceeds Management Policy.	860,354,819	99.9458%	300,645	0.0349%	165,925	0.0193%
7.	Amendments to the Rules for Implementing the Cumulative Voting Mechanism.	860,375,320	99.9482%	289,744	0.0337%	156,325	0.0182%
8.	Amendments to the Procedure for a Shareholder to Nominate a Person for Election as a Director.	860,354,819	99.9458%	303,945	0.0353%	162,625	0.0189%

SPECIAL RESOLUTIONS		FOR		AGAINST		ABSTAIN	
		NUMBER OF VOTES (SHARES)	PERCENTAGE	NUMBER OF VOTES (SHARES)	NUMBER OF VOTES (SHARES)	PERCENTAGE	NUMBER OF VOTES (SHARES)
9.	Amendments to the Articles of Association.	860,372,320	99.9478%	284,944	0.0331%	164,125	0.0191%
10.	Amendments to the Rules of Procedure for the General Meetings.	860,356,420	99.9460%	288,344	0.0335%	176,625	0.0205%
11.	Amendments to the Rules of Procedure for the Board Meetings.	860,380,319	99.9488%	284,745	0.0331%	156,325	0.0182%

Note:

1. For the purpose of calculating the result of the resolutions, all the votes for, against and abstain shall be regarded as voting rights.

2. Any discrepancies in the table between the total and the sum of the amounts listed are due to rounding.

3. Please refer to the Circular for a full text of the resolutions set out above.

The ordinary resolutions Nos. 1 to 8 above were passed by the affirmative votes representing at least half of the total number of Shares held by the attending Shareholders having voting rights who attended the EGM in person or by proxy, these resolutions were duly passed as ordinary resolutions of the Company.

The special resolutions Nos. 9 to 11 above were passed by the affirmative votes representing at least two-thirds of the total number of Shares held by the attending Shareholders having voting rights who attended the EGM in person or by proxy, these resolutions were duly passed as special resolutions of the Company.

(II) APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

References are made to the announcements of the Company dated October 28, 2025, and the Circular and the Notice both dated November 27, 2025 in relation to, among others, the proposed election of an independent non-executive Director of the third session of the Board. The Board is pleased to announce that as the relevant resolution was duly passed at the EGM, Prof. Tsang King Fung ("**Prof. Tsang**") has been appointed as an independent non-executive Director of the third session of the Board with effect from December 18, 2025.

The biographical details of Prof. Tsang were set out in the Circular under the requirements of Rule 13.51(2) of the Listing Rules. As at the date of this announcement, there has been no change in any such information. The Company has entered into a service agreement with Prof. Tsang for a term commencing from the date of this announcement until the expiration of the term of the third session of the Board.

Mr. Tsang Kwan Hung Benson (**"Mr. Tsang"**) has resigned as an independent non-executive Director and a member of the audit committee, the remuneration and appraisal committee and the nomination committee of the Board with effect from the appointment of Prof. Tsang as an independent non-executive Director on December 18, 2025. The Board would like to take this opportunity to express its sincere gratitude to Mr. Tsang for his valuable contributions to the Company during his tenure as an independent non-executive Director, and extend its welcome to Prof. Tsang for joining the Board.

(III) AMENDMENTS TO THE ARTICLES OF ASSOCIATION

References are made to the announcement of the Company dated October 28, 2025, and the Circular and the Notice both dated November 27, 2025. As confirmed by the legal advisers of the Company as to the laws of the PRC, the Board has obtained the proper authorization from the Shareholders at the EGM held on December 18, 2025 to increase in the registered capital and amend the Articles of Association as disclosed in the Circular.

By order of the Board
Pharmaron Beijing Co., Ltd.
康龍化成(北京)新藥技術股份有限公司
Dr. Lou Boliang
Chairman

Beijing, the PRC
December 18, 2025

As at the date of this announcement, the Board of Directors comprises Dr. Lou Boliang, Mr. Lou Xiaoqiang and Ms. Zheng Bei as executive Directors; Mr. Li Shing Chung Gilbert as employee representative Director; Mr. Li Jiaqing and Ms. Wan Xuan as non-executive Directors; Ms. Li Lihua, Prof. Tsang King Fung and Mr. Yu Jian as independent non-executive Directors.